Abstract
Since the introduction of 18 -F-fluorodeoxyglucose positron emission tomography (FDG-PET) to clinical oncologic imaging, studies have examined potential uses of the modality in the evaluation of breast cancer, including primary detection, initial staging, restaging, monitoring response to therapy, and predicting clinical prognosis. Although axillary lymph node staging using FDG-PET remains controversial, numerous studies have established a role for FDG-PET imaging in detecting locoregional recurrence and distant metastases. Furthermore, quantitative analysis of FDG uptake has been investigated as a potential tool for predicting the biological behavior of the tumor and inferring clinical prognosis. The recent introduction of combined positron emission tomography/x-ray computed tomography (PET/CT) systems has shown promise in improving the accuracy of PET imaging and potentially obviating the need for performing additional cross-sectional imaging in cases of suspected distant metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Seminars in Breast Disease: Radiologic, Pathologic and Surgical Considerations
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
